Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2014-005484-32-SE
EUCTR2014-005484-32-SE
Active, not recruiting
Not Applicable

Double-blind, randomized placebo controlled study on the effect from cortisone treatment of vestibular neuritis - function, subjective well-being and stress

und University0 sitesMarch 30, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
DrugsBetapredPrednisolone

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
und University
Status
Active, not recruiting
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 30, 2015
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
und University

Eligibility Criteria

Inclusion Criteria

  • •\-between 18 and 80 years of age
  • •\-disease duration \<48hrs
  • •\-clinical vestibular neuritis and no other neurological symptoms
  • •\-no dangerous HINTS (examination procedure)
  • •\-informed consent
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 160
  • •F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • •\-history of perforated ulcus
  • •\-tinnitus and hearing loss that started at the same time as vertigo
  • •\-psychiatric disease requiring treatment (other than mild depression treated with SSRIs)
  • •\-chronic otitis media
  • •\-serious infection, neutropenia or tuberculosis
  • •\-pregnancy or not wanting to prevent pregnancy during the time of medication (11 days)
  • •\-blood pressure; systolic \>180 and/or diastolic \>110
  • •\-impaired ability to make decision (dementia or up to treating physician)
  • •\-diabetes with ketoacidosis (Base excess \>\=2\)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Double-blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone. - TADTESTErectile dysfunctionClassification code 10061461
EUCTR2005-000852-34-GBSELARL du Dr Jacques BUVAT430
Completed
Not Applicable
Clinical study of IND02 on side effects of breast cancer chemotherapy
CTRI/2012/08/002883Indus Biotech Private Limited34
Recruiting
Not Applicable
Double-blind, randomized, placebo controlled study to REduce STEroids in Relapsing Nephrotic syndrome
NL-OMON47536Radboud Universitair Medisch Centrum80
Active, not recruiting
Phase 1
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000013775Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2012-000066-37-CZordmark Arzneimittel GmbH & Co. KG115
Active, not recruiting
Phase 1
Efficacy, safety, and tolerability of Ancrod in patients with sudden hearing losssudden sensorineural hearing loss (SSHL)MedDRA version: 20.0Level: LLTClassification code 10040016Term: Sensorineural hearing lossSystem Organ Class: 100000004854Therapeutic area: Diseases [C] - Ear, nose and throat diseases [C09]
EUCTR2012-000066-37-DEordmark Arzneimittel GmbH & Co. KG115